1. Introduction

Artificial Biological Governance Systems (ABGS) is a useful interdisciplinary concept describing the legal, ethical, institutional and technical frameworks used to regulate artificial or engineered biological systems. These may include genetically modified organisms (GMOs), synthetic biology, engineered cells, gene-editing technologies, artificial tissues, bioprinted organs, biological computing systems and AI-assisted biotechnology.

The term is not, by itself, a universally recognized legal doctrine or a separate statutory category. Its legal significance arises from the established rules governing biotechnology, biosafety, public health, environmental protection, privacy, intellectual property, human rights and administrative accountability.

The central question is:

How should the law govern biological systems that humans design, modify, manufacture or control, particularly when their behaviour, effects or risks may be difficult to predict?

For example, a genetically engineered microorganism released into the environment may reproduce, mutate or interact with other organisms. A gene-editing therapy may produce unintended effects in a patient. An AI system may recommend biological modifications without making its reasoning fully transparent. Each situation requires governance that addresses both scientific uncertainty and legal responsibility.

This explanation focuses primarily on Australian biotechnology law, with comparative international and common-law authorities where relevant.

2. Meaning and essential features

Artificial biological governance systems can be understood through six interconnected elements.

1. Biological design and intervention

Genetic engineering, synthetic DNA, gene editing, engineered microorganisms and cellular therapies.

2. Biosafety and biosecurity

Risk assessment, containment, prevention of accidental release, and controls against deliberate misuse.

3. Legal authorization

Licensing, regulatory approvals, clinical-trial permissions and environmental assessment.

4. Monitoring and traceability

Recordkeeping, adverse-event reporting, genetic-data management and post-release surveillance.

5. Rights and accountability

Informed consent, privacy, nondiscrimination, remedies and allocation of liability.

6. Adaptive governance

Revising approvals and safeguards when new scientific evidence reveals risks.

These elements operate together. A licence alone is insufficient if the organism is not monitored after release, and monitoring is ineffective if regulators lack the power to suspend a dangerous activity.

3. Australian legal framework

Australia regulates artificial biological systems through several overlapping legal regimes rather than one comprehensive ABGS statute.

The Commonwealth framework is supported by state and territory laws. The Office of the Gene Technology Regulator (OGTR) administers the gene technology scheme, including risk assessment, licensing, monitoring and enforcement. Other agencies regulate products within their respective jurisdictions.

Office of the Gene Technology Regulator

+2

Main regulatory principles

A. Prior authorization: Activities involving GMOs must be authorized under the applicable law unless a statutory exemption applies.

B. Risk assessment: Regulators evaluate potential harm, exposure pathways, containment measures and possible environmental consequences.

C. Precaution: Scientific uncertainty does not necessarily justify delaying reasonable protective action, particularly where serious or irreversible environmental harm is threatened. This principle is reflected in section 4 of the Gene Technology Act 2000.

Federal Register of Legislation

D. Proportionality: Regulatory controls should correspond to the nature and seriousness of the risk, while remaining consistent with the legislation.

E. Continuing supervision: Approval should not be treated as a guarantee of permanent safety. Monitoring, reporting and reassessment may be necessary when circumstances change.

4. Important case laws

The following decisions establish important principles relevant to artificial biological governance. Not all are direct challenges to a biological regulatory licence; several concern patentability, property rights, administrative legality or the limits of governmental power.

Case 1: Diamond v Chakrabarty, 447 U.S. 303 (1980)

Jurisdiction: United States Supreme Court

Facts: Ananda Chakrabarty developed a genetically engineered bacterium capable of breaking down multiple components of crude oil. The dispute concerned whether the living, artificially constructed microorganism could qualify as patentable subject matter.

Decision: The Supreme Court held that the engineered bacterium was patentable under the applicable US patent statute because it was a human-made invention rather than merely a naturally occurring organism.

Justia U.S. Supreme Court Center

+1

Legal principle: A biological invention may receive intellectual-property protection when it satisfies the relevant statutory requirements. The fact that an invention is alive does not automatically exclude it from patentability.

Relevance to ABGS: The case illustrates the distinction between creating a biological technology and governing its use. A patent does not itself establish biosafety, authorize environmental release or remove the need for regulatory approval.

Case 2: D'Arcy v Myriad Genetics Inc [2015] HCA 35

Jurisdiction: High Court of Australia

Facts: Myriad Genetics claimed patent rights concerning isolated nucleic acid associated with BRCA1 mutations relevant to cancer susceptibility. The dispute raised the question of whether isolated genetic material constituted a patentable invention.

Decision: The High Court unanimously held that the relevant claims did not qualify as a patentable invention under the Australian Patents Act 1990. Isolating naturally occurring genetic information did not, in substance, make that information an invention of the claimed kind.

High Court of Australia

+1

Legal principle: Human intervention and commercial usefulness are not sufficient by themselves to make naturally occurring genetic information patentable.

Relevance to ABGS: Governance must distinguish between biological discoveries, engineered products and genuinely inventive applications. This helps prevent intellectual-property rights from being used to claim exclusive control over naturally occurring human genetic information.

Case 3: Association for Molecular Pathology v Myriad Genetics, Inc., 569 U.S. 576 (2013)

Jurisdiction: United States Supreme Court

Facts: The dispute concerned patents over the BRCA1 and BRCA2 genes and their relationship to hereditary breast and ovarian cancer.

Decision: The Court held that naturally occurring DNA segments are not patentable merely because they have been isolated. It distinguished naturally occurring DNA from synthetically created complementary DNA (cDNA), which may be patentable subject to the applicable legal requirements.

LII / Legal Information Institute

Legal principle: Discovering and isolating something that exists in nature is legally different from creating a qualifying invention.

Relevance to ABGS: This distinction matters for genetic testing, access to diagnostic technologies, biotechnology research and the allocation of rights over biological information. The Australian Myriad decision is the more directly relevant authority for Australian patent law.

Case 4: Monsanto Canada Inc v Schmeiser, 2004 SCC 34

Jurisdiction: Supreme Court of Canada

Facts: Farmer Percy Schmeiser cultivated canola containing patented genetic material associated with Monsanto's herbicide-resistant technology. The dispute concerned infringement of patent rights.

Decision: The Supreme Court of Canada found patent infringement on the facts. It did not, however, award Monsanto a profit-based remedy because the evidence did not establish that Schmeiser had gained a profit attributable to the patented invention. The Court distinguished the case from innocent discovery of stray patented plants.

SCC Cases

Legal principle: Patent rights can apply to genetically modified biological material, but infringement and remedies depend on the particular facts and applicable law.

Relevance to ABGS: The case raises governance issues involving accidental genetic spread, seed contamination, farming practices, licensing and the balance between patent holders and farmers. It does not establish that every farmer whose land contains a patented organism automatically infringes a patent.

Case 5: Harvard College v Canada (Commissioner of Patents), 2002 SCC 76

Jurisdiction: Supreme Court of Canada

This dispute concerned a patent application for a genetically modified mouse developed for cancer research, commonly known as the Harvard Oncomouse.

Decision: The Court held that the claimed higher life form was not patentable as a “manufacture” or “composition of matter” under the Canadian patent legislation then in force.

Legal principle: The scope of patentable biological subject matter depends on statutory wording and the jurisdiction concerned.

Relevance to ABGS: The case demonstrates that legal governance of engineered animals must account for differences between patent rights, animal welfare, research ethics and biosafety. A ruling in one jurisdiction should not be assumed to determine patentability elsewhere.

Case 6: Waller v James [2006] HCA 16

Jurisdiction: High Court of Australia

Facts: The case involved allegations that medical practitioners negligently failed to investigate and warn parents about a genetic condition relevant to an IVF programme and antenatal care.

Decision: The High Court considered whether the child born with the inherited condition could recover damages for so-called wrongful life. The Court rejected the child's claim on the legal reasoning applicable to that cause of action.

High Court of Australia

Relevance to ABGS: The decision illustrates that genetic technologies and reproductive interventions raise questions of professional responsibility, informed decision-making and the limits of negligence remedies. It is not a general immunity for negligent biotechnology practices.

5. Administrative accountability and regulatory decision-making

Artificial biological governance also concerns the legality of decisions made by regulators, particularly when scientific evidence is complex or partly generated by algorithms.

In Australia, relevant review mechanisms may include:

Judicial review under the Administrative Decisions (Judicial Review) Act 1977 (Cth), where applicable.

Review under section 39B of the Judiciary Act 1903 (Cth).

Statutory merits review where legislation provides for it.

Internal regulatory reconsideration, complaints and compliance mechanisms where available.

Courts generally examine legality rather than simply substituting their preferred scientific judgment for that of a regulator. Grounds of review may include jurisdictional error, procedural unfairness, legal error, failure to consider relevant matters or improper exercise of statutory power.

Federal Court of Australia

+2

Automated biological governance

Suppose an AI system evaluates applications for genetically modified organism research licences. It assigns risk scores based on genetic sequences, laboratory containment procedures and historical incident data.

Potential legal problems include:

Lack of statutory authority: An agency cannot assume that a statutory decision-making power permits unrestricted delegation to an automated system.

Procedural unfairness: Applicants may need a meaningful opportunity to address adverse information, depending on the governing law.

Unexplained outcomes: An opaque risk score may make errors difficult to detect or challenge.

Data quality: Biased or incomplete datasets may produce unreliable safety assessments.

Responsibility: The regulator and relevant decision-makers must remain accountable for compliance with their legal duties.

In iDecide: the legal implications of automated decision-making, Justice Melissa Perry discussed the importance of legal authority, verification, audit mechanisms and human review in automated government decision-making. This is a judicial discussion rather than a binding judgment establishing a biotechnology-specific rule.

Federal Court of Australia

+1

6. Practical application: engineered microorganisms

Consider a company developing an engineered microorganism to remove pollutants from contaminated soil.

A sound governance framework would require the company and relevant regulators to address the following issues.

Research and classification: Determine whether the organism and proposed activity fall within the applicable gene technology legislation.

Risk assessment: Examine toxicity, survival, reproduction, mutation, gene transfer and effects on non-target organisms.

Authorization: Obtain any necessary licences, approvals or permissions before undertaking regulated activities.

Containment and release: Establish appropriate laboratory controls and assess whether environmental release is permissible.

Monitoring: Maintain records, investigate incidents and report matters as required by the relevant approval and legislation.

Remedies and liability: Determine responsibility for environmental damage, personal injury, regulatory breaches and contractual losses.

The OGTR's framework specifically addresses risks from GMOs, including potential environmental effects and the possibility that some consequences may be difficult to reverse.

Office of the Gene Technology Regulator

+1

7. Major legal challenges

These responses must be adapted to the technology and statutory scheme; no single safeguard automatically resolves every risk.

8. International governance and human rights

Artificial biological systems may engage international environmental and health frameworks, including the Cartagena Protocol on Biosafety, where applicable to the activity and jurisdiction. The Protocol addresses the safe handling, transport and use of living modified organisms resulting from modern biotechnology, particularly in relation to biodiversity and transboundary movement.

International human-rights principles may also be relevant when biological technologies affect bodily integrity, privacy, equality, reproductive autonomy or access to healthcare. Their enforceability depends on the applicable domestic legislation, treaties and legal proceedings.

Three distinctions are particularly important:

Scientific permission is not legal permission: Evidence that a technology works does not automatically authorize its use.

Patentability is not regulatory approval: A patent grants defined intellectual-property rights; it does not certify safety.

Ethical acceptance is not statutory compliance: Ethical review may be essential but cannot replace mandatory legal authorization.

9. Recommendations for an effective governance system

An effective artificial biological governance framework should incorporate:

Risk-based classification of biological systems.

Independent scientific and ethical review for high-risk activities.

Clear statutory responsibility for approval and enforcement.

Transparent reasons for important regulatory decisions.

Traceability and post-approval monitoring.

Procedures for suspending or revising approvals when new risks emerge.

Appropriate protection of genetic and medical information.

Accessible review mechanisms and effective remedies.

International cooperation where biological risks cross borders.

Periodic legislative review as scientific capabilities develop.

10. Conclusion

Artificial Biological Governance Systems provide a useful framework for understanding how law should regulate engineered organisms, genetic technologies, biological medicines and increasingly automated biotechnology.

The principal case-law lessons are that artificially created biological inventions may qualify for patent protection (Diamond v Chakrabarty), naturally occurring genetic information cannot automatically be monopolized (D'Arcy v Myriad Genetics), patent rights over engineered biological material must be assessed according to the applicable law (Monsanto v Schmeiser), and biotechnology-related professional negligence must be examined through established principles of duty and remedies (Waller v James).

Ultimately, effective governance requires a balance between scientific innovation, public health, environmental protection, individual rights and accountable decision-making. The core principle is that biological innovation must remain subject to lawful authorization, proportionate safeguards, continuing oversight and meaningful accountability.

Research note: ABGS is used here as an analytical umbrella term, not as the name of an established Australian cause of action or standalone statute. The cases discussed illustrate related legal principles; they do not collectively establish a single ABGS doctrine. This explanation is educational and not a substitute for advice on a particular dispute.